This profile translates into potentactivity in xenograft tumor models with translocations in FGFR1 (8p11-translocatedmyeloid leukemia), FGFR2 (cholangiocarcinoma), and FGFR3 (urothelial carcinoma). Here, FGFR2 is linked to cholangiocarcinoma.